[Anticoagulation therapy in patients with infectious endocarditis: a therapeutic dilemma].

J. Thompson,E. Loeliger

1984-10-20

Abstract:

What problem does this paper attempt to address?

Electron microscopic observations on the fine structure of the glomerular basement membrane.

T. Mori,K. Saito,T. Nishihara,N. Tamaki,K. Nagai

1971-09-01

Abstract:
Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis

Johnie Rose,Rachael L Hawthorn,Brook Watts,Mendel E Singer

DOI: https://doi.org/10.1136/bmj.b3653

2009-09-25

BMJ

Abstract:Objectives: To examine the public health impact of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in a birth cohort in India, and to estimate the cost effectiveness and affordability of such a programme. Design: Decision analytical Markov model encompassing all direct medical costs. Infection risk and severity depended on age, number of previous infections, and vaccination history; probabilities of use of inpatient and outpatient health services depended on symptom severity. Data sources: Published clinical, epidemiological, and economic data. When possible, parameter estimates were based on data specific for India. Population Simulated Indian birth cohort followed for five years. Main outcome measures: Decrease in rotavirus gastroenteritis episodes (non-severe and severe), deaths, outpatient visits, and admission to hospital; incremental cost effectiveness ratio of vaccination expressed as net cost in 2007 rupees per life year saved. Results: In the base case, vaccination prevented 28,943 (29.7%) symptomatic episodes, 6981 (38.2%) severe episodes, 164 deaths (41.0%), 7178 (33.3%) outpatient visits, and 812 (34.3%) admissions to hospital per 100,000 children. Vaccination cost 8023 rupees (about pound100, euro113, $165) per life year saved, less than India's per capita gross domestic product, a common criterion for cost effectiveness. The net programme cost would be equivalent to 11.6% of the 2006-7 budget of the Indian Department of Health and Family Welfare. Model results were most sensitive to variations in access to outpatient care for those with severe symptoms. If this parameter was increased to its upper limit, the incremental cost effectiveness ratio for vaccination still fell between one and three times the per capita gross domestic product, meeting the World Health Organization's criterion for "cost effective" interventions. Uncertainty analysis indicated a 94.7% probability that vaccination would be cost effective according to a criterion of one times per capita gross domestic product per life year saved, and a 97.8% probability that it would be cost effective according to a criterion of three times per capita gross domestic product. Conclusions: Across a wide range of assumptions, mass RIX4414 vaccination in India would probably prevent substantial morbidity and mortality at a cost per life year saved below typical thresholds of cost effectiveness. The opportunity costs of such a programme in this or similar settings, however, should be weighed up carefully.
The evidence base for rotavirus vaccination in India: Current status, future needs

Niranjan Bhat,Elisabeth Vodicka,Allison Clifford,Kanduri Balaji Ananth,Ashish Bavdekar,Arup Deb Roy,Umesh Parashar,Jacqueline Tate,Pradeep Haldar,Gagandeep Kang

DOI: https://doi.org/10.1016/j.vaccine.2024.126551

IF: 4.169

2024-12-01

Vaccine

Abstract:Rotavirus is a leading cause of severe diarrheal disease in infants and young children worldwide. Vaccination offers the best protection against this disease, and two rotavirus vaccines were developed in India and included in its routine immunization program. The Government of India's decision to adopt this intervention was supported by a solid base of evidence from clinical trials, as well as substantial research regarding rotavirus disease burden and the potential health and economic value of immunization. Following program implementation, multiple studies were initiated, including three evaluations of effectiveness and several investigations regarding intussusception. These additional data regarding vaccine impact, safety, and delivery from post-introduction evaluations in conditions of real-world use will further strengthen and sustain the immunization program. This manuscript evaluates the status of existing and forthcoming evidence regarding rotavirus vaccination in India through a literature review and consultation with relevant stakeholders. Studies evaluating vaccine impact, effectiveness, safety, health economics, and acceptability, as well as operational and programmatic research, were included in the review. Overall, we found that the evidence base did not contain any major gaps. Nevertheless, additional smaller-scale research studies would be valuable in providing a more complete picture of rotavirus vaccine performance and benefit. Documentation of India's experience with rotavirus vaccines may provide lessons learned for other countries in the Asia region, where rotavirus disease burden remains high, yet vaccine adoption has been slow, as well as for countries worldwide that may be considering implementation of the Indian-made rotavirus vaccines.

immunology,medicine, research & experimental
Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule

Nicholas Geard,Richard Bradhurst,Nefel Tellioglu,Vicka Oktaria,Jodie McVernon,Amanda Handley,Julie E Bines

DOI: https://doi.org/10.1080/21645515.2022.2139097

2022-11-30

Abstract:Rotavirus infection is a common cause of severe diarrheal disease and a major cause of deaths and hospitalizations among young children. Incidence of rotavirus has declined globally with increasing vaccine coverage. However, it remains a significant cause of morbidity and mortality in low-income countries where vaccine access is limited and efficacy is lower. The oral human neonatal vaccine RV3-BB can be safely administered earlier than other vaccines, and recent trials in Indonesia have demonstrated high efficacy. In this study, we use a stochastic individual-based model of rotavirus transmission and disease to estimate the anticipated population-level impact of RV3-BB following delivery according to either an infant (2, 4, 6 months) and neonatal (0, 2, 4 months) schedule. Using our model, which incorporated an age- and household-structured population and estimates of vaccine efficacy derived from trial data, we found both delivery schedules to be effective at reducing infection and disease. We estimated 95-96% reductions in infection and disease in children under 12 months of age when vaccine coverage is 85%. We also estimate high levels of indirect protection from vaccination, including 78% reductions in infection in adults over 17 years of age. Even for lower vaccine coverage of 55%, we estimate reductions of 84% in infection and disease in children under 12 months of age. While open questions remain about the drivers of observed lower efficacy in low-income settings, our model suggests RV3-BB could be effective at reducing infection and preventing disease in young infants at the population level.
Irradiation enhances the support of haemopoietic cell transmigration, proliferation and differentiation by endothelial cells

M. Gaugler,C. Squiban,M. Mouthon,P. Gourmelon,A. Van der Meeren

DOI: https://doi.org/10.1046/j.1365-2141.2001.02852.x

2001-06-01

British Journal of Haematology

Abstract:Endothelial cells (ECs) are a critical component of the bone marrow stroma in the regulation of haemopoiesis. Recovery of bone marrow aplasia after radiation exposure depends, in part, on the repair of radiation‐induced endothelial damage. Therefore, we assessed the ability of an irradiated human bone marrow EC line (TrHBMEC) to support transmigration, proliferation and differentiation of CD34+ bone marrow cells either irradiated or not in transendothelial migration or co‐culture models. Radiation‐induced EC damage was reflected by an increased release of soluble intercellular adhesion molecule (sICAM)‐1 and platelet endothelial cell adhesion molecule (PECAM)‐1. Irradiation of TrHBMECs with a 10 Gy dose strongly enhanced the transmigration of CD34+ cells, granulo‐monocytic progenitors (CFU‐GM) and erythroid progenitors (BFU‐E). While ICAM‐1 and PECAM‐1 expression on irradiated TrHBMECs was increased, only antibodies against PECAM‐1 inhibited the radiation‐induced enhanced transmigration of haemopoietic cells. Irradiation of TrHBMECs (5–15 Gy) also increased proliferation and differentiation towards the granulo‐monocytic lineage of co‐cultured CD34+ cells, as well as colony formation by those cells and the production of interleukin 6 (IL‐6), IL‐8, granulocyte colony‐stimulating factor (CSF) and granulocyte‐macrophage CSF. Irradiated TrHBMECs were more capable of stimulating irradiated (1,2 Gy) CD34+ cells and haemopoietic progenitors than non‐irradiated TrHBMECs. Together, these results suggest that, despite the radiation‐induced damage, irradiated ECs may favour haemopoietic reconstitution after radiation exposure.
An ensemble approach to predicting the impact of vaccination on rotavirus disease in Niger

Jaewoo Park,Joshua Goldstein,Murali Haran,Matthew Ferrari

DOI: https://doi.org/10.1016/j.vaccine.2017.09.020

IF: 4.169

2017-10-01

Vaccine

Abstract:Recently developed vaccines provide a new way of controlling rotavirus in sub-Saharan Africa. Models for the transmission dynamics of rotavirus are critical both for estimating current burden from imperfect surveillance and for assessing potential effects of vaccine intervention strategies. We examine rotavirus infection in the Maradi area in southern Niger using hospital surveillance data provided by Epicentre collected over two years. Additionally, a cluster survey of households in the region allows us to estimate the proportion of children with diarrhea who consulted at a health structure. Model fit and future projections are necessarily particular to a given model; thus, where there are competing models for the underlying epidemiology an ensemble approach can account for that uncertainty. We compare our results across several variants of Susceptible-Infectious-Recovered (SIR) compartmental models to quantify the impact of modeling assumptions on our estimates. Model-specific parameters are estimated by Bayesian inference using Markov chain Monte Carlo. We then use Bayesian model averaging to generate ensemble estimates of the current dynamics, including estimates of R<sub>0</sub>, the burden of infection in the region, as well as the impact of vaccination on both the short-term dynamics and the long-term reduction of rotavirus incidence under varying levels of coverage. The ensemble of models predicts that the current burden of severe rotavirus disease is 2.6-3.7% of the population each year and that a 2-dose vaccine schedule achieving 70% coverage could reduce burden by 39-42%.

immunology,medicine, research & experimental
Health impact of rotavirus vaccination in China

Sharomi Oluwaseun,Chelsey Yang,Su Jian Si Tu,Jia Yin,Yan Song,Qiang Sun,Nabi Kanibir,Susanne Hartwig,Cristina Carias

DOI: https://doi.org/10.1080/21645515.2024.2386750

2024-09-15

Human Vaccines & Immunotherapeutics

Abstract:Rotavirus (RV) vaccines have demonstrated substantial effectiveness in reducing the healthcare burden caused by gastroenteritis (RVGE) worldwide. This study aims to understand the differential impact of RV vaccination in reducing RVGE burden in children under 7 years old in China. A Markov Model was used to investigate the health impact of introducing two different RV vaccines into the Chinese population. The analysis was conducted for RV5, a live pentavalent human-bovine reassortant vaccine, and Lanzhou Lamb RV (LLR), a live-attenuated monovalent RV vaccine, separately, by comparing the strategy of each vaccine to no vaccination within a Chinese birth cohort, including 100,000 children modeled until 7 years of age. The vaccination scenario assumed a vaccination coverage of 2.5%, 2.5%, 90% and 5% for doses one, two, three and no vaccine, respectively, for both vaccines. Strategies with RV5, LLR, and no vaccination were associated with 9,895, 49,069, and 64,746 symptomatic RV infections, respectively. RV5 and LLR were associated with an 85% and 24% reduction in the total symptomatic RV infections, respectively, suggesting that the health benefits of RV5 are at least three-fold greater than those associated with the LLR. Further, strategies with RV5 and LLR resulted in an estimated 206 and 59-year increase in quality-adjusted life years (QALYs), respectively. Sensitivity and scenario analyses supported the robustness of the base-case findings. Use of RV vaccine is expected to improve RV-associated health outcomes and its adoption will help alleviate the burden of RVGE in China. RV5 use will result in significantly better health outcomes.

immunology,biotechnology & applied microbiology
Estimating the global impact of rotavirus vaccines on child mortality

Andrew Clark,Sarwat Mahmud,Frederic Debellut,Clint Pecenka,Mark Jit,Jamie Perin,Jacqueline Tate,Heidi M Soeters,Robert E Black,Mathuram Santosham,Colin Sanderson

DOI: https://doi.org/10.1016/j.ijid.2023.10.005

Abstract:Objectives: We estimated the global impact of rotavirus vaccines on deaths among children under five years old by year. Methods: We used a proportionate outcomes model with a finely disaggregated age structure to estimate rotavirus deaths prevented by vaccination over the period 2006-2019 in 186 countries. We ran deterministic and probabilistic uncertainty analyses and compared our estimates to surveillance-based estimates in 20 countries. Results: We estimate that rotavirus vaccines prevented 139,000 under-five rotavirus deaths (95% uncertainty interval 98,000-201,000) in the period 2006-2019. In 2019 alone, rotavirus vaccines prevented 15% (95% uncertainty interval 11-21%) of under-five rotavirus deaths (0.5% of child mortality). Assuming global use of rotavirus vaccines and coverage equivalent to other co-administered vaccines could prevent 37% of under-five rotavirus deaths (1.2% of child mortality). Our estimates were sensitive to the choice of rotavirus mortality burden data and several vaccine impact modeling assumptions. The World Health Organization's recommendation to remove age restrictions in 2012 could have prevented up to 17,000 rotavirus deaths in the period 2013-2019. Our modeled estimates of rotavirus vaccine impact were broadly consistent with estimates from post-vaccination surveillance sites. Conclusion: Rotavirus vaccines have made a valuable contribution to global public health. Enhanced rotavirus mortality prevention strategies are needed in countries with high mortality in under-5-year-old children.
Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin

E. Pesanti

DOI: https://doi.org/10.1128/AAC.18.1.208

IF: 5.938

1980-07-01

Antimicrobial Agents and Chemotherapy

Abstract:The ability of rifampin to kill Staphylococcus aureus which have been ingested by normal mouse peritoreal macrophages in vitro has been investigated. In contrast to data which have been reported from experiments with other cell types, in this system rifampin was no more active than was penicillin against the two strains tested.
Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria

John D. Anderson,Clinton J. Pecenka,Karoun H. Bagamian,Richard D. Rheingans

DOI: https://doi.org/10.1371/journal.pone.0232941

IF: 3.7

2020-05-29

PLoS ONE

Abstract:Child mortality from rotavirus gastroenteritis remains high in Nigeria, representing 14% of all rotavirus deaths worldwide. Here, we examine the potential impact and cost-effectiveness of national rotavirus vaccine introduction in geographic and economic subpopulations of Nigeria. We projected the health and economic outcomes of rotavirus vaccination in children over the first five years of life using a spreadsheet-based model. We modeled child populations using national survey data on rotavirus mortality risk factors and vaccination coverage to predict burden and impact across regional and wealth quintile subpopulations within Nigeria. Our base case considered introduction of a general rotavirus vaccine, modeled to encompass characteristics of existing vaccines, versus no vaccine. Base case costs were estimated from the government perspective, assuming Gavi subsidies, over the first five years. We also present estimates from the cost of vaccination from the perspective of Gavi. We explored uncertainty in model parameters through probabilistic uncertainty, one-way sensitivity, and scenario analyses. According to our estimates, rotavirus enteritis was responsible for 47,898 [95% Uncertainty Limits: 35,361; 63,703] child deaths per year, with approximately 80% of the national burden concentrated in the three northern regions of Nigeria. Rotavirus vaccination was estimated to prevent 6,454 [3,960; 9,721] deaths, 13% [9%; 18%] of the national annual RV burden. National ICERs for rotavirus vaccination from the Nigerian government and Gavi perspectives were US$47 [$18; $105] and $62 [$29; $130] per DALY averted, respectively. General rotavirus vaccination was projected to reduce rotavirus mortality by only 6% [4%; 9%] in the North West region compared to 35% [24%; 47%] in the South East region. Base case ICERs ranged from US$25 [10; 56] per DALY averted in North West to US$64 [18; 157] per DALY averted in South South. Gavi perspective ICERs ranged from US$33 [$15; $68] in North West to US$88 [35; 191] per DALY averted in South South. According to one-way sensitivity analyses, ICERs were most sensitive to vaccine efficacy, followed by estimated administrative costs and rotavirus mortality. Disparities in mortality reduction were largely driven by inequality in vaccination coverage across regions and between socioeconomic subpopulations. Due to high, persistent, and inequitable burden of rotavirus in Nigeria, routine vaccination with any of these rotavirus vaccines would be an high impact and cost-effective strategy in reducing child mortality.

multidisciplinary sciences
[Saliva research: now and in the future].

A. van Nieuw Amerongen

Nederlands Tijdschrift voor Tandheelkunde

Abstract:In the near future salivary research will most likely play a rather important role in daily dental practice. The dentist will be expected to gather data concerning the patient's nutrition, medical history, oral complaints and xerostomia as perceived by the patient. In addition he may perform the following plain measurements: secretion rate of whole saliva in resting condition and after stimulation, and some parameters of importance for caries. The biochemical analysis of whole saliva and glandular salivas can be performed only in specialized laboratory. New developments are to be expected on the field of biotechnical synthesis of salivary protective factors, that is to say, histatins and cystatins in the nearby future and mucins on the longer term. New saliva substitutes and mouth rinses will be made on the basis of these artificially made proteins, not only to relieve xerostomia, but also to prevent oral infection and inflammation.
Old—and With Severe Heart Failure: Telemonitoring by Using Digital Pen Technology in Specialized Homecare: System Description, Implementation, and Early Results

L. Lind,G. Carlgren,D. Karlsson

DOI: https://doi.org/10.1097/CIN.0000000000000252

2016-08-01

Abstract:Telehealth programs for heart failure have been studied using a variety of techniques. Because currently a majority of the elderly are nonusers of computers and Internet, we developed a home telehealth system based on digital pen technology. Fourteen patients (mean age, 84 years [median, 83 years]) with severe heart failure participated in a 13-month pilot study in specialized homecare. Participants communicated patient-reported outcome measures daily using the digital pen and health diary forms, submitting a total of 3 520 reports. The reports generated a total of 632 notifications when reports indicated worsening health. Healthcare professionals reviewed reports frequently, more than 4700 times throughout the study, and acted on the information provided. Patients answered questionnaires and were observed in their home environment when using the system. Results showed that the technology was accepted by participants: patients experienced an improved contact with clinicians; they felt more compliant with healthcare professionals’ advice, and they felt more secure and more involved in their own care. Via the system, the healthcare professionals detected heart failure–related deteriorations at an earlier stage, and as a consequence, none of the patients were admitted into hospital care during the study.
Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction

A Bennett,L Pollock,K C Jere,V E Pitzer,U Parashar,J E Tate,R S Heyderman,C Mwansambo,N French,O Nakagomi,M Iturriza-Gomara,D Everett,N A Cunliffe,N Bar-Zeev,VacSurv Consortium

DOI: https://doi.org/10.1016/j.vaccine.2018.04.030

IF: 4.169

2018-11-12

Vaccine

Abstract:Introduction: Despite increased use of vaccine in routine immunisation, rotavirus remains a major cause of acute gastroenteritis (AGE) in low-income countries. We describe rotavirus prevalence and hospitalisation in Malawi pre and four years post vaccine introduction; provide updated vaccine effectiveness (VE) estimates; and assess rotavirus vaccine indirect effects. Methods: Children under five years of age presenting to a referral hospital in Blantyre with AGE were recruited. Stool samples were tested for rotavirus using Enzyme Immunoassay. The change in rotavirus prevalence was evaluated using Poisson regression. Time series analysis was used to further investigate trends in prevalence over time. VE against rotavirus diarrhoea of any severity was estimated using logistic regression. Indirect effects were estimated by evaluating rotavirus prevalence in unvaccinated children over time, and by comparing observed reductions in incidence of rotavirus hospitalisation to those expected based on vaccine coverage and trial efficacy estimates. Results: 2320 children were included. Prevalence of rotavirus in hospitalised infants (<12 months) with AGE decreased from 69/139(49.64%) prior to vaccine introduction to 197/607(32.45%) post-vaccine introduction (adjusted RR 0.67[95% CI 0.55, 0.82]). Prevalence in children aged 12-23 months demonstrated a less substantial decline: 15/37(40.54%) pre- and 122/352(34.66%) post-vaccine introduction (adjusted RR 0.85, 95% CI 0.57, 1.28). Adjusted VE was 61.89%(95% CI 28.04-79.82), but lower in children aged 12-23 months (31.69% [95% CI -139.03 to 80.48]). In hospitalised infants with rotavirus disease, the observed overall effect of the vaccine was 9% greater than expected according to vaccine coverage and efficacy estimates. Rotavirus prevalence among unvaccinated infants declined post-vaccine introduction (RR 0.70[95% CI 0.55-0.80]). Conclusions: Following rotavirus vaccine introduction in Malawi, prevalence of rotavirus in hospitalised children with AGE has declined significantly, with some evidence of an indirect effect in infants. Despite this, rotavirus remains an important cause of severe diarrhoea in Malawian children, particularly in the second year of life.
Thermodynamics of urban population flows.

A. Hernando,A. Plastino

DOI: https://doi.org/10.1103/PhysRevE.86.066105

2012-06-29

Abstract:Orderliness, reflected via mathematical laws, is encountered in different frameworks involving social groups. Here we show that a thermodynamics can be constructed that macroscopically describes urban population flows. Microscopic dynamic equations and simulations with random walkers underlie the macroscopic approach. Our results might be regarded, via suitable analogies, as a step towards building an explicit social thermodynamics.
Burden and Molecular Epidemiology of Rotavirus Causing Diarrhea among Under-Five Children: A Hospital-based Study from Eastern India

Arpit Kumar Shrivastava,N Samarasimha Reddy,Sidhartha Giri,Priyadarshi Soumyaranjan Sahu,Mirabai Das,Nirmal Kumar Mohakud,Rashmi Ranjan Das

DOI: https://doi.org/10.4103/jgid.jgid_16_19

Abstract:Background: Rotavirus (RVA) causes severe gastroenteritis in under-five children, and there are many diverse strains of the virus that are localized to different parts of the world. Objectives: To study the burden and molecular epidemiology of RVA causing gastroenteritis among children from Eastern India. Materials and methods: This hospital-based cross-sectional study included children under-five with gastroenteritis. Demographic and clinical parameters were recorded in a predesigned pro forma. Stool samples collected from these children were initially screened for RVA VP6 antigen by enzyme immunoassay (EIA). Each EIA-positive sample was then subjected to RNA extraction, followed by reverse transcription, and heminested multiplex polymerase chain reaction for genotyping of RVA strains. Results: Of 320 included children, RVA was detected in 30.62% (98/320) cases by EIA. The highest incidence for RVA-positive cases (34.61%) was observed among children in the age group of 24-36 months, followed by 0-12 months (33.04%). Of the 97 completely typed samples, single genotype was detected in 85 (87.62%) samples with either G (VP7) or P (VP4) types. However, mixed genotypes were detected in 12 (11.21%) samples. G3P[8] (44.09%) was the most common genotype, followed by G1P[8] (32.65%), G2[P4] (5.10%), G1[P6] (3.06%), and G9[P4] (1.02%). Conclusions: The present study found RVA positivity in 30.62% of children with gastroenteritis, with the highest burden among 24-36 months old. The predominant genotypes were G1, G3, and P[8]. Further large-scale/multicentric studies should be conducted to document the diversity of circulating RVA genotypes in this region for giving inputs for vaccination strategy.
Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years

Christopher Troeger,Ibrahim A. Khalil,Puja C. Rao,Shujin Cao,Brigette F. Blacker,Tahmeed Ahmed,George Armah,Julie E. Bines,Thomas G. Brewer,Danny V. Colombara,Gagandeep Kang,Beth D. Kirkpatrick,Carl D. Kirkwood,Jason M. Mwenda,Umesh D. Parashar,William A. Petri,Mark S. Riddle,A. Duncan Steele,Robert L. Thompson,Judd L. Walson,John W. Sanders,Ali H. Mokdad,Christopher J. L. Murray,Simon I. Hay,Robert C. Reiner

DOI: https://doi.org/10.1001/jamapediatrics.2018.1960

2018-10-01

JAMA Pediatrics

Abstract:Importance: Rotavirus infection is the global leading cause of diarrhea-associated morbidity and mortality among children younger than 5 years.Objectives: To examine the extent of rotavirus infection among children younger than 5 years by country and the number of deaths averted because of the rotavirus vaccine.Design, Setting, and Participants: This report builds on findings from the Global Burden of Disease Study 2016, a cross-sectional study that measured diarrheal diseases and their etiologic agents. Models were used to estimate burden in data-sparse locations.Exposure: Diarrhea due to rotavirus infection.Main Outcomes and Measures: Rotavirus-associated mortality and morbidity by country and year and averted deaths attributable to the rotavirus vaccine by country.Results: Rotavirus infection was responsible for an estimated 128 500 deaths (95% uncertainty interval [UI], 104 500-155 600) among children younger than 5 years throughout the world in 2016, with 104 733 deaths occurring in sub-Saharan Africa (95% UI, 83 406-128 842). Rotavirus infection was responsible for more than 258 million episodes of diarrhea among children younger than 5 years in 2016 (95% UI, 193 million to 341 million), an incidence of 0.42 cases per child-year (95% UI, 0.30-0.53). Vaccine use is estimated to have averted more than 28 000 deaths (95% UI, 14 600-46 700) among children younger than 5 years, and expanded use of the rotavirus vaccine, particularly in sub-Saharan Africa, could have prevented approximately 20% of all deaths attributable to diarrhea among children younger than 5 years.Conclusions and Relevance: Rotavirus-associated mortality has decreased markedly over time in part because of the introduction of the rotavirus vaccine. This study suggests that prioritizing vaccine introduction and interventions to reduce diarrhea-associated morbidity and mortality is necessary in the continued global reduction of rotavirus infection.

pediatrics
Cost effectiveness analysis of rotavirus vaccination in Indonesia

Jarir At Thobari,Emma Watts,Natalie Carvalho,Jonathan Hasian Haposan,Andrew Clark,Frédéric Debellut,Asal Wahyuni Erlin Mulyadi,Julitasari Sundoro,Mardiati Nadjib,Sri Redzeki Hadinegoro,Julie Bines,Yati Soenarto

DOI: https://doi.org/10.1016/j.vaccine.2024.126478

IF: 4.169

2024-11-06

Vaccine

Abstract:Background Rotavirus (RV) remains the most common cause of morbidity and mortality due to acute gastroenteritis (AGE) in children under five. In Indonesia, RV is responsible for 60 % of severe AGE and 40 % of non-severe AGE in these children. This study assessed the cost-effectiveness of introduction of rotavirus vaccines (RVV) into the National Immunization Program in Indonesia. Methods We conducted a cost-effectiveness analysis (CEA) of RVV introduction in Indonesia, assuming a three-dose vaccine schedule based on the planned introduction proposed by the Strategic Advisory Group of Experts on Immunization. The analysis involved an initial introduction of an imported RVV (Rotavac®, Bharat Biotech, India) followed by a staged implementation of the locally produced RVV (Bio Farma, Indonesia) from both health system and societal perspectives. The primary outcome measure was the incremental cost (2019 USD) per disability-adjusted life year (DALY) averted, compared to no vaccination. We took model inputs from an Indonesian cost-of-illness study, national information systems and scientific literature, covering disease incidence, hospitalization, mortality, healthcare costs, and vaccine related factors. Our analyses included univariate and probabilitistic sensitivity analyses to assess various parameters. Findings The cost of a 10-year vaccination program is 82.6 million USD and can potentially prevent 7.3 million cases of rotavirus and 0.42 million DALYs. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the staged program is 464 USD per DALY averted (12 % of Indonesia's gross domestic product (GDP) per capita). From a healthcare sector perspective, ICER is similar at 479 USD (13 % GDP per capita). Interpretation The introduction of RVV into the National Immunization Program is likely to be highly cost-effective in Indonesia. Funding This work was supported by funding agreement with the Murdoch Children's Research Institute (MCRI), PATH, and the Indonesian Technical Advisory Group on Immunization (ITAGI).

immunology,medicine, research & experimental
Barriers to community treatment of patients with dual diagnoses.

R. Howland

DOI: https://doi.org/10.1176/PS.41.10.1134

1990-10-01

Abstract:services for mental health treatment and those for substance abuse treat ment. Given the extent of problems faced by dual diagnosis patients and their relatively poor fit in either the mental health on the substance abuse systems alone, specialized services would seem appropriate. However, few community programs exist to provide such specialized services, and those that do probably could not adequately serve the large number of patientswho might benefit. An alter native would be to coordinate exist ing services from each system, a practice that is unfortunately the ex ception rather the rule (6). This paper describes some of the barriers to the adequate provision of clinical services for dual diagnosis patients and recommends ways of ovencorn ing these barriers.
The impact of rotavirus vaccination on acute diarrhea in Thai children under 5 years of age in the first year of universal implementation of rotavirus vaccines in the National Immunization Program (NIP) in Thailand: a 6-year analysis

Busara Charoenwat,Kunanya Suwannaying,Watuhatai Paibool,Napat Laoaroon,Sumitr Sutra,Kaewjai Thepsuthammarat,Suphasarang Sirirattanakul

DOI: https://doi.org/10.1186/s12889-023-16958-0

IF: 4.5

2023-10-27

BMC Public Health

Abstract:Background: Two types of rotavirus vaccines (RVs), Rotarix (RV1) and RotaTeq (RV5), were licensed as optional vaccines in 2012 and became part of the National Immunization Program (NIP) in the fiscal year 2020 in Thailand. The main objective was to evaluate the impact of rotavirus vaccines on the burden of acute diarrheal severity ranging from outpatient visits, diarrheal-related admission or deaths in the pre-NIP period (fiscal year 2015-2019) and in the fiscal year 2020. The minor objectives were assessed on the monthly admission rate, rotavirus vaccine coverage rate and rotavirus vaccine completed dose (RotaC). Methods: Data regarding OPD, admission, and death cases under the Thailand National Health Coverage (NHC) from fiscal year 2015-2020, which were recorded as International Classification of Diseases and Related Health Problem 10th (ICD-10), were analyzed. Results: The burden of diarrheal-related disease diminished after the rotavirus vaccine was introduced in the fiscal year 2020 when compared to the previous 5 fiscal years. The OPD visit rate decreased from 10.1 to 8.3 visits per 100 person-years (P < 0.001), or a 17.8% reduction (incidence rate ratio (IRR) = 0.82; 95% confidence interval (CI): 0.81 to 0.82). The admission rate significantly declined from 31.4 to 30.5 cases per 1,000 person-years, (P < 0.001), or a 2.9% reduction (IRR = 0.97; 95% CI: 0.96 to 0.98). The diarrheal-related mortality rate also subsided from 10.2 to 8.1 cases per 100,000 person-years (P 0.3), or a 20.0% reduction (IRR = 0.88; 95% CI: 0.50 to 1.22). The major population in both admissions and deaths was infants under 1 year of age (P < 0.001). Seasonality was seen as a constant bimodal pattern, with a significant decrease in monthly admissions after 6 months of rotavirus vaccine introduction to NIP (P < 0.001). RotaC was 37.4% in the first year of NIP. Conclusions: The rotavirus vaccine had a potential benefit for reducing the diarrheal disease burden, especially in infants under one year of age. Seasonality outbreaks of acute diarrhea subsided after the rotavirus vaccine was introduced. The RotaC was fairly low in the first year of the NIP. The quality of the rotavirus vaccine should be warranted. Trial registration: Number TCTR20220120003 , date of registration: 20/01/2022, site: Thai Clinical Trials Registry.
Commentary on "Factors associated with emergency department visits in asthma exacerbation".

J. Trevor,M. Dransfield

DOI: https://doi.org/10.14423/SMJ.0000000000000276

2015-05-01

Abstract:Although the more regular use of inhaled corticosteroids (ICS) in patients with moderate to severe asthma has led to a reduction in admission rates for exacerbations, rates of emergency department (ED) visits remain unacceptably and inexplicably high. Previous work has shown that nonwhite race, low socioeconomic status, and greater asthma severity are associated with ED visits, but these factors do not fully explain the variation in the use of emergency services. In this issue of the Southern Medical Journal, Wells et al further explore the conundrum by examining factors associated with ED visits in an underserved and low income population using retrospective data obtained from three ambulatory care centers. The purpose of the studywas to provide data for quality improvement programs designed to reduce ED utilization among patients with asthma. The study was designed as a caseYcontrol analysis wherein cases consisted of asthmatics with one or more ED visit during a 2-year time period, and controls consisted of asthmatics with one or more outpatient clinic visits but no ED visits during the same 2 years. The authors found that cases were more likely to have been prescribed an ICS in addition to a second controller medication and less likely to have been receiving ICS monotherapy or have been given short-acting A-agonists (SABA) than controls in the year before the index visit. The authors propose that individuals prescribed an ICS plus additional therapy were more likely to use the ED as a reflection of greater disease severity. This assumption is supported by the finding that cases also were more likely to have received a referral for asthma specialty care in the 12 months previously, but it is surprising that they were less likely to have received a prescription for SABA. SABA are recommended for all asthma patients as the most effective means of quickly treating increased symptoms, and lack of availability would certainly put patients at increased risk for needing ED services. Because records from other healthcare systemswere not available for this study, it is possible that these patients were prescribed SABA elsewhere, but this finding raises concerns about drawing a cause-and-effect conclusion about the relation between prescribed medications and ED visitation. Consistent with our present understanding, cases alsowere less likely to receive an influenza vaccination despite clear evidence that the vaccine is safe and effective and that infection is associated with an increased risk of hospitalization for asthma. The lack of provision of the influenza vaccine may be an indicator of less consistent use of primary care services among these individuals, as suggested by the long time to primary care follow-up ofmore than 2 months, but it also could be a reflection of patient preferences as fears about vaccinations continue to hamper the broad use of these critical public health interventions. It is also noted that nonsmokers were more likely than smokers to seek ED care. As the authors hypothesize, smoking may be a self-limited vice in this population that is suspected to have more severe disease; however, this runs counter to the literature, which suggests that asthmatic smokers are more likely to have severe symptoms and a decreased response to ICS therapy. An alternative theory is that the smoking population may be misdiagnosed as having asthma. Because bronchodilator reversibility testing and methacholine challenge test results are not available, it is possible that smoking individuals included in the study may not be asthmatic but rather had acute bronchitis or bronchiolitis associated with a better prognosis. Interestingly, race was not found to correlate with ED visits in the Wells et al study. Although there is debate in the literature on this point, data tend to favor nonwhite race being associated with increased ED use and hospitalization among asthmatics, even when controlling for socioeconomic differences. It is possible that the power to detect differences in the utilization of emergency services among different racial and ethnic groups was lost as a result of the uniformly underserved Invited Commentary

[Anticoagulation therapy in patients with infectious endocarditis: a therapeutic dilemma].

Electron microscopic observations on the fine structure of the glomerular basement membrane.

Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis

The evidence base for rotavirus vaccination in India: Current status, future needs

Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule

Irradiation enhances the support of haemopoietic cell transmigration, proliferation and differentiation by endothelial cells

An ensemble approach to predicting the impact of vaccination on rotavirus disease in Niger

Health impact of rotavirus vaccination in China

Estimating the global impact of rotavirus vaccines on child mortality

Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin

Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria

[Saliva research: now and in the future].

Old—and With Severe Heart Failure: Telemonitoring by Using Digital Pen Technology in Specialized Homecare: System Description, Implementation, and Early Results

Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction

Thermodynamics of urban population flows.

Burden and Molecular Epidemiology of Rotavirus Causing Diarrhea among Under-Five Children: A Hospital-based Study from Eastern India

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years

Cost effectiveness analysis of rotavirus vaccination in Indonesia

Barriers to community treatment of patients with dual diagnoses.

The impact of rotavirus vaccination on acute diarrhea in Thai children under 5 years of age in the first year of universal implementation of rotavirus vaccines in the National Immunization Program (NIP) in Thailand: a 6-year analysis

Commentary on "Factors associated with emergency department visits in asthma exacerbation".